(Reuters) - BioDelivery Sciences International Inc said its pain drug failed to meet the main goal of a late-stage study, sending the drugmaker's shares down nearly 30 percent premarket.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment